BioLineRx Ltd.
BLRXNasdaq
$2.90
↓ -2.7%Jul 17 close · end-of-day
Price
1Y↓ -37.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Motixafortide, a peptide, has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization. It is also developing AGI-134, an immuno-oncology agent, and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.
- CEO
- Philip A. Serlin
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Website
- biolinerx.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.